Bioventus (BVS) Income from Non-Controlling Interests (2020 - 2026)

Bioventus (BVS) posted Income from Non-Controlling Interests of $744000.0 for Q1 2026, up 137.59% on a QoQ basis from -$2.0 million in Q4 2025, and up 208.61% year-over-year from $241078.5 in Q1 2025.

Bioventus (BVS) Income from Non-Controlling Interests (2020 - 2026) Analysis & Trends

Bioventus' Income from Non-Controlling Interests history runs 7 years deep, the most recent figure standing at $744000.0 for Q1 2026.

  • Quarterly Income from Non-Controlling Interests rose 208.61% year-over-year to $744000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (up 41.2% YoY) and the FY2023 annual result came in at -$24.5 million, down 75.26% from the prior year.
  • Income from Non-Controlling Interests was $744000.0 for Q1 2026 at Bioventus, up from -$2.0 million in the prior quarter.
  • Across five years, Income from Non-Controlling Interests topped out at $10.7 million in Q4 2024 and bottomed at -$14.9 million in Q2 2023.
  • A 5-year average of -$2.4 million and a median of -$1.5 million in 2023 frame the typical range for Income from Non-Controlling Interests.
  • Annual changes were most pronounced in 2022 — Income from Non-Controlling Interests sank 764.95% — and 2024, when it soared 786.47%.
  • Bioventus' Income from Non-Controlling Interests stood at -$4.7 million in 2022, then jumped by 66.84% to -$1.6 million in 2023, then soared by 786.47% to $10.7 million in 2024, then plunged by 118.48% to -$2.0 million in 2025, then jumped by 137.59% to $744000.0 in 2026.
  • Business Quant data shows BVS's Income from Non-Controlling Interests at $744000.0 in Q1 2026, -$2.0 million in Q4 2025, and $601000.0 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Inc. Minority (Qtr)
1 Abbott Laboratories 183.20 Bn 175.91 Bn 6.27 Bn -
2 Stryker 128.87 Bn 125.99 Bn 3.81 Bn -
3 Medtronic 108.88 Bn 99.66 Bn 6.41 Bn 16.00 Mn
4 Boston Scientific 68.33 Bn 66.87 Bn 3.61 Bn -2.00 Mn
5 Edwards Lifesciences 47.31 Bn 43.64 Bn 1.29 Bn -
6 Dexcom 28.65 Bn 27.53 Bn 750.30 Mn -
7 GE HealthCare Technologies 28.40 Bn 26.11 Bn 1.98 Bn 22.00 Mn
8 Smith & Nephew 26.97 Bn 26.40 Bn - -
9 Koninklijke Philips 25.55 Bn 22.42 Bn 2.07 Bn -5.85 Mn
10 Bioventus 811.59 Mn 775.75 Mn 90.77 Mn 744,000.00

Historic Data

Download Data
DateValue
Mar 28, 2026 744,000.00
Dec 31, 2025 -1.98 Mn
Sep 27, 2025 601,000.00
Jun 28, 2025 1.81 Mn
Mar 29, 2025 -685,000.00
Dec 31, 2024 10.71 Mn
Sep 28, 2024 -570,000.00
Jun 29, 2024 -8.62 Mn
Mar 30, 2024 -1.49 Mn
Dec 31, 2023 -1.56 Mn
Apr 1, 2023 -14.94 Mn
Dec 31, 2022 -4.70 Mn
Oct 1, 2022 -9.25 Mn
Apr 2, 2022 -3.53 Mn
Dec 31, 2021 8.26 Mn
Oct 2, 2021 -1.30 Mn
Jul 3, 2021 -6.65 Mn
Apr 3, 2021 -408,000.00
Dec 31, 2020 -525,000.00
Sep 26, 2020 -492,000.00